期刊文献+

Parkin蛋白C端的表达及抗体的制备

Expression of c-terminal of Parkin in E.coli and the preparation of antiserum
下载PDF
导出
摘要 目的 :构建Parkin基因 3’端的表达质粒 ,在大肠杆菌中表达并制备多克隆抗体。方法 :构建Parkin基因3’端 (937~ 195 9bp)的谷氨酰胺硫转移酶 (glutathion sulfate transferase ,GST)融合表达质粒 ,在JM 10 5中获得表达。用Triton 10 0 (1% )和Tween 2 0 (1% )处理 ,并用亲和层析纯化表达产物 ,将其免疫新西兰兔 ,用免疫印迹分析收获的兔抗血清。结果 :构建的ParkinC表达质粒在JM 10 5中获得表达 ,以分子量为 4 2kD的包涵体存在 ;目的蛋白纯度为 95 % ;得到效价为 1∶6 4的抗血清 ;免疫印迹分析表明 ,制备的抗血清可与鼠脑细胞抽提物中 5 1 6kD的蛋白产生特异的免疫反应。结论 :Parkin蛋白C端在 JM 10 5 Objective To clone and express 3' terminal of Parkin gene in E.coli, and prepare its antiserum for further study. Methods The glutathion sulfate transferase (GST) fusion expression plasmid of 3' terminal of Parkin gene (937~1959 bp) was constructed and transferred to JM 105. After being treated with Triton 100 (1%) and Tween 20 (1%) and purified with affinity chromatograph, GST Parkin C was used to immunize New Zealand rabbits to acquire antiserum. Antiserum was analysed with immunoblot. Results The GST Parkin C protein was expressed in JM 105, existing in the form of inclusion body with a molecular weight of around 42 kD; The purity of GST Parkin C was up to 95%; the titer of antiserum was 1∶64; Immunoblotting showed that the prepared antiserum could react specifically with 51.6 kD protein extracted from the mouse brain. Conclusion A high level of expression of GST Parkin C is obtained in JM 105, and its antiserum can be prepared successfully.
出处 《湖南医科大学学报》 CSCD 北大核心 2002年第1期1-3,共3页 Bulletin of Hunan Medical University
基金 国家杰出青年基金 (3 992 80 16) 国家重大基础研究 (973 )项目 (G19980 5 10 0 2 )
关键词 Parkin蛋白 C端 原核表达 多克隆抗体 Parkinson's病 帕金森氏病 Parkin protein C terminal prokaryotic expression polyclonal antibody Parkinson's disease
  • 相关文献

参考文献9

  • 1[1]Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinson's disease[J]. Nature, 1998,392:605-608.
  • 2[2]Horowitz JM, Vernace VA, Myers J, et al. Immunodetection of Parkin protein in vertebrate and invertebrate brains: a comparative study using specific antibodies[J]. J Chem Neuroanat, 2001,21:75-93.
  • 3[3]Horowitz JM, Myers J, Vernace VA, et al. Spatial distribution, cellular integration and stage development of Parkin protein in Xenopus brain[J]. Brain Res Dev Brain Res, 2001,126:31-41.
  • 4[4]Schapira AH. Mitochondrial dysfunction in neurodegenerative disease[J]. Biochim Biophys Acta, 1998,1366:25-33.
  • 5[5]Sambrook J, Fritsh EF, Maniatis T, et al. Molecular cloning: A laboratory manual[M]. 2nd ed, New York: Cold Spring Harbor Laboratory Press, 1989.34-69.
  • 6[6]Ba DN. Contemporary immunological technology and application[M]. Beijing: Beijing Medical University and Xiehe Medical University United Publishers, 1998.189-243.
  • 7[7]Zhang Y, Gao J, Chung KK, et al. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1[J]. Proc Natl Acad Sci USA, 2000,97:13354-13359.
  • 8[8]Alvarez V, Guisasola LM, Moreira VG, et al. Early-onset Parkinson's disease associated with a new parkin mutation in a Spanish family[J]. Neurosci Lett, 2001,313:108-110.
  • 9[9]Kitada T, Asakawa S, Minoshima S, et al. Molecular cloning, gene expression, and identification of splicing variant of mouse parkin gene[J]. Mamm Genome, 2000,11:417.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部